16 Temperature Controlled Stage used as a Mini-Reactor to Study Heterogeneous Catalysis
Researchers at the University of South Carolina are using the Linkam CCR1000 stage as a mini-reactor (in-situ Raman cell). They are using Raman spectroscopy to investigate the oxidation of carbon monoxide over rhodium based catalysts (zeolite and alumina are used as supports). Specifically, they are looking at the structure and morphology of the active sites of rhodium containing catalysts under working conditions. They apply variable techniques to determine the metal electronic state and its coordination environment (in case of supported rhodium complexes) during the catalytic cycle. Raman spectroscopy is used to understand the activity of rhodium oxide species. Catalysis by ‘single site’ catalysts is of particular interest to the researchers.
The catalysts are prepared in a nitrogen atmosphere and generally should be considered as air and water sensitive materials. Therefore, the team have to load the samples in the reactor/cell (CCR1000) in a glove box filled with nitrogen. Two valves have been installed on the CCR1000 so they are able to transfer the cell to the Raman spectrometer to avoid contact with air. At the spectrometer, they connect it to the gas distribution system allowing the CO/O2/He mixture to flow right through the reactor/cell. The main objective of the experiment is to follow formation and possibly decomposition of rhodium oxide species on a surface of supports during carbon monoxide oxidation at different temperatures. They explain “the motivation for our research is basically gaining fundamental knowledge on the catalysis by ‘non-metallic’ species. In other words, we are looking at the catalysis by supported metal clusters (4-10 atoms) or supported metal complexes (1 atom). At this scale catalyst properties change drastically which often results in enhanced catalytic activity.” When asked about the Linkam system they also noted the 'big advantage is a precise temperature control which is important when doing multiple experiments at different temperatures.'
SPECTROSCOPY Circle no. 562
New Powder Characteristics Tester Launched
Hosokawa Micron Ltd announce the launch of the Hosokawa Powder Characteristics Tester, type PT-X, the latest version of the well known laboratory unit which is used to determine powder characteristics when designing powder handling and processing systems.
The new unit the PT-X has been updated with a number of features to make it easier to use and more operator friendly. The new design allows the unit to be used in conjunction with computers for data recording, delivering a clear visual display of analysis results to enable the operator to evaluate the results simply and quickly.
In 1965 Dr R.L Carr developed seven powder characteristics to help in the design and control of powder handling and processing systems. These seven characteristics can be measured by the PT-X unit; Angle of Repose, Compressibility, Angle of Spatula, Cohesion, Angle of Fall, Dispersibility and Angle of Difference. In addition three auxiliary values, Aerated Bulk Density, Packed Bulk Density and Uniformity, can also be evaluated by the Hosokawa Powder Characteristics Tester to determine valued results for flowability and floodability of dry powders.
LAUDA Integral XT. Extreme Temperature Dynamics.
The new PT-X looks very different from previous versions and is more compact in design. The unit offers computer control via a touch screen 12.5 inch tablet PC using a core i5 processor with Windows 7 Professional operating system which can reduce analysis time. Reduced operator intervention ensures analysis accuracy and repeatability.
The unit’s inner wall forms part of the structure making the PT-X easier to clean and an optional integrated HEPA filter, for dust protection is available, as is a vacuum cleaner.
The Hosokawa Powder Characteristics Tester PT-X offers complete powder characterisation in a single instrument. LAB PRODUCTS Circle no. 563
New Hepatitis C Assay Plays an Important Part in Patient Diagnosis and Management
With an estimated 216,000 individuals chronically infected in the UK (England 161,000, Northern Ireland 4,000, Scotland 39,000, Wales 12,000), hepatitis C (HCV) remains a major public health problem; and HCV-related end stage liver disease and mortality continue to increase. The Health Protection Agency states that it is necessary to sustain and enhance efforts to raise awareness, prevent new infections, increase diagnosis, and treat more individuals with infection.
Process thermostats for external temperature control from -90 up to 300 °C.
The immense power of the LAUDA Integral XT process thermostats unfolds fast and precisely. The low thermal value, combined with intricate technology allowes temperature steps between -90 and 300 °C. Whether it is temperature range, heat performance or ease of operation: the LAUDA Integral XT line sets the standards.
www.lauda.de
LAUDA DR. R. WOBSER GMBH & CO. KG · P. O. Box 12 51 · 97912 Lauda-Königshofen Germany · Phone: +49 (0) 9343 503-0 · Fax: +49 (0) 9343 503-222 · E-mail:
info@lauda.de
Circle no. 565 The new Roche Elecsys® anti-HCV II assay can play an
effective part in this strategy, as it is used to demonstrate the presence of antibodies against HCV during acute and chronic stages of disease, and after a passed infection.
Due to the high rate of asymptomatic infections, clinical diagnosis of hepatitis C is difficult and screening assays are of major importance.
The Roche Elecsys anti-HCV II assay provides 100% clinical sensitivity for all known genotypes, leading to early detection of infection and patient-oriented decision making.
With high specificity in blood donors (99.84%)) and samples from clinical routine, pregnant women and dialysis patients, use of the Elecsys anti-HCV II assay increases laboratory testing efficiencies. To optimise workflows and provide operational cost savings, the ready-to-use liquid reagents have a long onboard stability of 31 days on all Roche immunoassay platforms.
The new assay complements the Roche serology assay menu that includes assays for Hepatitis A, Hepatitis B, Hepatitis C, HIV, TORCH, Herpes, Syphilis and other infectious diseases.
LAB PRODUCTS Circle no. 564
LABMATE UK & IRELAND - APRIL 2012
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36
